Molecular and Translational Classifications of DAMPs in Immunogenic Cell Death
Open accessThe DOI matches its Crossref record; 248 of the 248 references it cites were found in a registry or an index.
Abstract
The immunogenicity of malignant cells has recently been acknowledged as a critical determinant of efficacy in cancer therapy. Thus, besides developing direct immunostimulatory regimens, including dendritic cell-based vaccines, checkpoint-blocking therapies, and adoptive T-cell transfer, researchers have started to focus on the overall immunobiology of neoplastic cells. It is now clear that cancer cells can succumb to some anticancer therapies by undergoing a peculiar form of cell death that is characterized by an increased immunogenic potential, owing to the emission of the so-called "damage-associated molecular patterns" (DAMPs). The emission of DAMPs and other immunostimulatory factors by cells succumbing to immunogenic cell death (ICD) favors the establishment of a productive interface with the immune system. This results in the elicitation of tumor-targeting immune responses associated with the elimination of residual, treatment-resistant cancer cells, as well as with the establishment of immunological memory. Although ICD has been characterized with increased precision since its discovery, several questions remain to be addressed. Here, we summarize and tabulate the main molecular, immunological, preclinical, and clinical aspects of ICD, in an attempt to capture the essence of this phenomenon, and identify future challenges for this rapidly expanding field of investigation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Riganti, C., Castella, B., Kopecka, J., Campia, I., Coscia, M., Pescarmona, G., Bosia, A., Ghigo, D., & Massaia, M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0060975 · Cited by 50
Self-citationRetractedPD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
STRING v10: protein–protein interaction networks, integrated over the tree of life
Szklarczyk, D., Franceschini, A., Wyder, S., Forslund, K., Heller, D., Huerta-Cepas, J., Simonovic, M., Roth, A., Santos, A., Tsafou, K. P., et al. (2015) · Nucleic Acids Research · doi:10.1093/nar/gku1003 · Cited by 10,436
Photodynamic therapy of cancer: An update
Agostinis, P., Berg, K., Cengel, K. A., Foster, T. H., Girotti, A. W., Gollnick, S. O., Hahn, S. M., Hamblin, M. R., Juzeniene, A., Kessel, D., et al. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20114 · Cited by 5,145
Self-citationThe immune contexture in human tumours: impact on clinical outcome
Fridman, W. H., Pagès, F., Sautès-Fridman, C., & Galon, J. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3245 · Cited by 4,981
The future of immune checkpoint therapy
Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878
Tolerance, Danger, and the Extended Family
Matzinger, P. (1994) · Annual Review of Immunology · doi:10.1146/annurev.iy.12.040194.005015 · Cited by 4,820
Neoantigens in cancer immunotherapy
Schumacher, T. N., & Schreiber, R. D. (2015) · Science · doi:10.1126/science.aaa4971 · Cited by 4,783
Research works printed but not linked: 9
- Liao, 1974, Comparative immunogenicity of irradiated, neuraminidase treated, and fused cells of a strain-restricted sarcoma, Z Krebsforsch klin Onkol Cancer Res Clin Oncol, 82, 133, 10.1007/BF00284498 · doi:10.1007/bf00284498
- Milas, 1976, Nonspecific immunotherapy of malignant tumors, Radiology, 118, 211, 10.1148/118.1.211 · doi:10.1148/118.1.211
- Bogden, 1978, Influence of surgery, irradiation, chemotherapy, and immunotherapy on growth of a metastasizing rat mammary adenocarcinoma, Natl Cancer Inst Monogr, 97
- Dickson, 1982, Hyperthermia: the immune response and tumor metastasis, Natl Cancer Inst Monogr, 61, 183
- Suit, 1980, Assessment of the response of tumours to radiation: clinical and experimental studies, Br J Cancer Suppl, 4, 1
- Richert, 1986, Promotion of tumor antigenicity in EL-4 leukemia cells by hydrostatic pressure, Cancer Immunol Immunother, 22, 119, 10.1007/BF00199125 · doi:10.1007/bf00199125
- Gough, 2004, Induction of cell stress through gene transfer of an engineered heat shock transcription factor enhances tumor immunogenicity, Gene Ther, 11, 1099, 10.1038/sj.gt.3302274 · DOI
- Bian, 2011, Caspase- and p38-MAPK-dependent induction of apoptosis in A549 lung cancer cells by Newcastle disease virus, Arch Virol, 156, 1335, 10.1007/s00705-011-0987-y · doi:10.1007/s00705-011-0987-y
- Tubiana, 1986, Klaas Breur medal lecture 1985. The growth and progression of human tumors: implications for management strategy, Radiother Oncol, 6, 167, 10.1016/S0167-8140(86)80151-7 · DOI
Cited by
A proteomic atlas of senescence-associated secretomes for aging biomarker development
Basisty, N., Kale, A., Jeon, O. H., Kuehnemann, C., Payne, T., Rao, C., Holtz, A., Shah, S., Sharma, V., Ferrucci, L., et al. (2020) · PLOS Biology · doi:10.1371/journal.pbio.3000599 · Cited by 1,348
Neutrophil: A Cell with Many Roles in Inflammation or Several Cell Types?
Rosales, C. (2018) · Frontiers in Physiology · doi:10.3389/fphys.2018.00113 · Cited by 1,334
“As a consequence of cell death, alarmins, collectively referred to as “damage-associated molecular patterns” (DAMPs), enhance sensing of dying cells by innate immune cells (Zitvogel et al., 2010; Garg et al., 2015b).”
BackgroundFerroptosis, necroptosis, and pyroptosis in anticancer immunity
Tang, R., Xu, J., Zhang, B., Liu, J., Liang, C., Hua, J., Meng, Q., Yu, X., & Shi, S. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00946-7 · Cited by 1,273
Consensus guidelines for the definition, detection and interpretation of immunogenic cell death
Galluzzi, L., Vitale, I., Warren, S., Adjemian, S., Agostinis, P., Martinez, A. B., Chan, T. A., Coukos, G., Demaria, S., Deutsch, E., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000337 · Cited by 1,119
Self-citationTargeting immunogenic cell death in cancer
Ahmed, A., & Tait, S. W. G. (2020) · Molecular Oncology · doi:10.1002/1878-0261.12851 · Cited by 930
Defining the role of the tumor vasculature in antitumor immunity and immunotherapy
Schaaf, M. B., Garg, A. D., & Agostinis, P. (2018) · Cell Death & Disease · doi:10.1038/s41419-017-0061-0 · Cited by 629
Self-citationTargeting immunogenic cancer cell death by photodynamic therapy: past, present and future
Alzeibak, R., Mishchenko, T. A., Shilyagina, N. Y., Balalaeva, I. V., Vedunova, M. V., & Krysko, D. V. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001926 · Cited by 565
Self-citationVaccination with early ferroptotic cancer cells induces efficient antitumor immunity
Efimova, I., Catanzaro, E., Van der Meeren, L., Turubanova, V. D., Hammad, H., Mishchenko, T. A., Vedunova, M. V., Fimognari, C., Bachert, C., Coppieters, F., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001369 · Cited by 520
Self-citationCell death and immunity in cancer: From danger signals to mimicry of pathogen defense responses
Garg, A. D., & Agostinis, P. (2017) · Immunological Reviews · doi:10.1111/imr.12574 · Cited by 440
Self-citationMyeloid Cell-Derived Arginase in Cancer Immune Response
Grzywa, T. M., Sosnowska, A., Matryba, P., Rydzynska, Z., Jasinski, M., Nowis, D., & Golab, J. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00938 · Cited by 424
Self-citationMetal Drugs and the Anticancer Immune Response
Englinger, B., Pirker, C., Heffeter, P., Terenzi, A., Kowol, C. R., Keppler, B. K., & Berger, W. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00396 · Cited by 355
Integrating next-generation dendritic cell vaccines into the current cancer immunotherapy landscape
Garg, A. D., Coulie, P. G., Van den Eynde, B. J., & Agostinis, P. (2017) · Trends in Immunology · doi:10.1016/j.it.2017.05.006 · Cited by 340
Self-citationTrial watch: Immunogenic cell death induction by anticancer chemotherapeutics
Garg, A. D., More, S., Rufo, N., Mece, O., Sassano, M. L., Agostinis, P., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1386829 · Cited by 276
Self-citationWhich cell death modality wins the contest for photodynamic therapy of cancer?
Mishchenko, T., Balalaeva, I., Gorokhova, A., Vedunova, M., & Krysko, D. V. (2022) · Cell Death & Disease · doi:10.1038/s41419-022-04851-4 · Cited by 276
Self-citationGarg, A. D., Vandenberk, L., Koks, C., Verschuere, T., Boon, L., Van Gool, S. W., & Agostinis, P. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aae0105 · Cited by 270
Self-citationTrial watch: TLR3 agonists in cancer therapy
Le Naour, J., Galluzzi, L., Zitvogel, L., Kroemer, G., & Vacchelli, E. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1771143 · Cited by 239
Trial watch: chemotherapy-induced immunogenic cell death in immuno-oncology
Vanmeerbeek, I., Sprooten, J., De Ruysscher, D., Tejpar, S., Vandenberghe, P., Fucikova, J., Spisek, R., Zitvogel, L., Kroemer, G., Galluzzi, L., et al. (2020) · OncoImmunology · doi:10.1080/2162402x.2019.1703449 · Cited by 227
“paclitaxel, docetaxel), bleomycin and vinca alkaloids.(15,113,333)”
Self-citationThe Regulation of Inflammation by Innate and Adaptive Lymphocytes
Cronkite, D. A., & Strutt, T. M. (2018) · Journal of Immunology Research · doi:10.1155/2018/1467538 · Cited by 222
“Host cell-derived danger signals or alarmins such as heat shock proteins, uric acid crystals, high-mobility group box 1, S100 proteins, serum amyloid A, and products of purine metabolism released from damaged or stressed cells are sensed by DAMP receptors such as RAGE, TLRs, and purinergic receptors [38, 39].”
The Unfolded Protein Response in Immunogenic Cell Death and Cancer Immunotherapy
Rufo, N., Garg, A. D., & Agostinis, P. (2017) · Trends in Cancer · doi:10.1016/j.trecan.2017.07.002 · Cited by 207
“However, there is a significant inducer- and context-dependent plasticity in the amount, diversity, kinetics, and immunological activity of DAMPs, danger signals, and cytokines/chemokines emitted upon treatment (Table 1) [48,49].”
BackgroundSelf-citationOrigin and Consequences of Necroinflammation
Sarhan, M., Land, W. G., Tonnus, W., Hugo, C. P., & Linkermann, A. (2018) · Physiological Reviews · doi:10.1152/physrev.00041.2016 · Cited by 207
Self-citationHypericin in the Light and in the Dark: Two Sides of the Same Coin
Jendželovská, Z., Jendželovský, R., Kuchárová, B., & Fedoročko, P. (2016) · Frontiers in Plant Science · doi:10.3389/fpls.2016.00560 · Cited by 186
Necroptotic cell death in anti‐cancer therapy
Krysko, O., Aaes, T. L., Kagan, V. E., D'Herde, K., Bachert, C., Leybaert, L., Vandenabeele, P., & Krysko, D. V. (2017) · Immunological Reviews · doi:10.1111/imr.12583 · Cited by 173
Self-citationA Polymeric Hydrogel to Eliminate Programmed Death-Ligand 1 for Enhanced Tumor Radio-Immunotherapy
Shen, W., Pei, P., Zhang, C., Li, J., Han, X., Liu, T., Shi, X., Su, Z., Han, G., Hu, L., et al. (2023) · ACS Nano · doi:10.1021/acsnano.3c08875 · Cited by 165
Transplantation and Damage-Associated Molecular Patterns (DAMPs)
Land, W. G., Agostinis, P., Gasser, S., Garg, A. D., & Linkermann, A. (2016) · American Journal of Transplantation · doi:10.1111/ajt.13963 · Cited by 163
“Typically, HSPs and CALR, like other chaperones, can translocate to the surface of cells through the ER-toGolgi transfer and secretory pathway (210).”
BackgroundInfluentialSelf-citationFucikova, J., Truxova, I., Hensler, M., Becht, E., Kasikova, L., Moserova, I., Vosahlikova, S., Klouckova, J., Church, S. E., Cremer, I., et al. (2016) · Blood · doi:10.1182/blood-2016-08-731737 · Cited by 135
Self-citationType I interferons and dendritic cells in cancer immunotherapy
(2019) · International Review of Cell and Molecular Biology · doi:10.1016/bs.ircmb.2019.06.001 · Cited by 124
Self-citationGarg, A. D., Vandenberk, L., Fang, S., Fasche, T., Van Eygen, S., Maes, J., Van Woensel, M., Koks, C., Vanthillo, N., Graf, N., et al. (2017) · Cell Death & Differentiation · doi:10.1038/cdd.2017.15 · Cited by 120
“TLRs myeloid differentiation primary response 88/MyD88 pathway) or annexin-A1 (AnxA1),(3,7) known to operate at the dying cell-DC/macrophage interface.(3,24) However, not much clarity exists on dying cell-derived neutrophil-activating factors/danger signals.”
BackgroundSelf-citationA Proteomic Atlas of Senescence-Associated Secretomes for Aging Biomarker Development
(2019) · doi:10.1101/604306 · Cited by 110
Trial Watch: experimental TLR7/TLR8 agonists for oncological indications
Frega, G., Wu, Q., Le Naour, J., Vacchelli, E., Galluzzi, L., Kroemer, G., & Kepp, O. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1796002 · Cited by 108
Non-cell autonomous effects of the senescence-associated secretory phenotype in cancer therapy.
Saleh, T., Tyutynuk-Massey, L., Cudjoe, E. K., Idowu, M. O., Landry, J. W., & Gewirtz, D. A. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00164 · Cited by 85
Type I interferons and endoplasmic reticulum stress in health and disease
(2020) · International Review of Cell and Molecular Biology · doi:10.1016/bs.ircmb.2019.10.004 · Cited by 83
“Nevertheless, in case of cancer it has been shown that the PERK axis can facilitate the active secretion or, surface exposure of danger signals, like calreticulin (a well-established "eat me" signal) or, ATP (a short-range "find me" signal) during the process of apoptotic immunogenic cell death (ICD) (Garg et al., 201…”
Self-citationAnalysis of extracellular vesicles generated from monocytes under conditions of lytic cell death
Baxter, A. A., Phan, T. K., Hanssen, E., Liem, M., Hulett, M. D., Mathivanan, S., & Poon, I. K. H. (2019) · Scientific Reports · doi:10.1038/s41598-019-44021-9 · Cited by 60
Sun, Z., Zhao, M., Wang, W., Hong, L., Wu, Z., Luo, G., Lu, S., Tang, Y., Li, J., Wang, J., et al. (2023) · Cancer Letters · doi:10.1016/j.canlet.2022.216032 · Cited by 57
Insights into P-Glycoprotein Inhibitors: New Inducers of Immunogenic Cell Death
Kopecka, J., Godel, M., Dei, S., Giampietro, R., Belisario, D. C., Akman, M., Contino, M., Teodori, E., & Riganti, C. (2020) · Cells · doi:10.3390/cells9041033 · Cited by 41
Self-citation
Metadata
- Authors
- Garg, A. D., Galluzzi, L., Apetoh, L., Baert, T., Birge, R. B., Bravo-San Pedro, J. M., Breckpot, K., Brough, D., Chaurio, R., Cirone, M., Coosemans, A., Coulie, P. G., De Ruysscher, D., Dini, L., de Witte, P., Dudek-Peric, A. M., Faggioni, A., Fucikova, J., Gaipl, U. S., Golab, J., Gougeon, M.-L., Hamblin, M. R., Hemminki, A., Herrmann, M., Hodge, J. W., Kepp, O., Kroemer, G., Krysko, D. V., Land, W. G., Madeo, F., Manfredi, A. A., Mattarollo, S. R., Maueroder, C., Merendino, N., Multhoff, G., Pabst, T., Ricci, J.-E., Riganti, C., Romano, E., Rufo, N., Smyth, M. J., Sonnemann, J., Spisek, R., Stagg, J., Vacchelli, E., Vandenabeele, P., Vandenberk, L., Van den Eynde, B. J., Van Gool, S., Velotti, F., Zitvogel, L., & Agostinis, P.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2015-11-20
- Volume
- 6
- Pages
- 588-588
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W2173550086
- Cited by
- 410
- References
- 248
- FWCI
- 16.63
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.